SAB Biotherapeutics Inc
presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference.
The company said the DiversitAb platform can produce natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies against various disease targets without human donors.
The company also outlined data on SAB-185 for COVID-19 and SAB-176 for seasonal and pandemic influenza showing the candidates being effective against variants of several highly mutating viruses associated with the diseases.
SAB-185 exhibited equivalent neutralization of the Munich, Alpha, Beta, Gamma variants and a variant isolated from an immunocompromised patient.
It retained neutralization of the Delta variant AY.1 and multiple Omicron variants, with only modest losses of neutralization activity.
Prophylactic SAB-185 treatment protected the hamsters from death and minimized signs of infection when challenged with the variant viruses tested.
Phase 2a trial for SAB-176 met its primary endpoint of reducing the nasopharyngeal viral load in subjects challenged with H1N1 A/California/2009-like virus.
SAB-176 also met secondary endpoints of reducing symptoms by Day 4 and shortened the timeframe of the ability to culture virus in vitro, suggesting reduced viral shedding, and was safe and well tolerated.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.